virus recovery data for flub (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
virus recovery data for flub
Virus Recovery Data For Flub, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/virus+recovery+data+for+flub/Influenza+B+virus/10__3390_slash_pharmaceutics17030349-232-217-222
Average 99 stars, based on 16 article reviews
Virus Recovery Data For Flub, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/virus+recovery+data+for+flub/Influenza+B+virus/10__3390_slash_pharmaceutics17030349-232-217-222
Average 99 stars, based on 16 article reviews
virus recovery data for flub - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Neutralization:Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1 , Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1, Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Biomarker Discovery:Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1 , Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1, Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Control:Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1 , Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1, Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Formulation:Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1 , Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1, Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Virus:Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1 , Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1, Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Activity Assay:Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1 , Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( Article Title: In Vitro Development of Local Antiviral Formulations with Potent Virucidal Activity Against SARS-CoV-2 and Influenza Viruses Article Snippet: Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics17030349/s1, Figure S1: Physical characteristics (turbid or clear) of formulations containing DLM and surfactant at different ratios, measured 1 day after preparation and after a temperature cycling test (6 cycles); Table S1: Cytotoxicity and neutralization validation control data for oral formulation D in MDCK cells; Table S2: Cytotoxicity and neutralization validation control data for nasal formulation E in MDCK cells; Table S3: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S4: Virus recovery data for FluA(H1N1pdm) (A/Thailand/104/2009); Table S5: Virucidal activity of oral formulation D at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S6: Virucidal activity of nasal formulation E at a dilution of 1:32 against FluA(H1N1pdm) (A/Thailand/104/2009); Table S7: Test results for oral formulation D and nasal formulation E at a dilution of 1:32 against FluA( |